Fadlyana, E.; Rusmil, K.; Dwi Putra, M.G.; Fulendry, F.P.; Somantri, N.K.; Putri, A.D.; Sari, R.M.; Puspita, M.; Dewi, G.P.
Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents. Vaccines 2024, 12, 938.
https://doi.org/10.3390/vaccines12080938
AMA Style
Fadlyana E, Rusmil K, Dwi Putra MG, Fulendry FP, Somantri NK, Putri AD, Sari RM, Puspita M, Dewi GP.
Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents. Vaccines. 2024; 12(8):938.
https://doi.org/10.3390/vaccines12080938
Chicago/Turabian Style
Fadlyana, Eddy, Kusnandi Rusmil, Muhammad Gilang Dwi Putra, Frizka Primadewi Fulendry, Nitta Kurniati Somantri, Alvira Dwilestarie Putri, Rini Mulia Sari, Mita Puspita, and Gianita Puspita Dewi.
2024. "Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents" Vaccines 12, no. 8: 938.
https://doi.org/10.3390/vaccines12080938
APA Style
Fadlyana, E., Rusmil, K., Dwi Putra, M. G., Fulendry, F. P., Somantri, N. K., Putri, A. D., Sari, R. M., Puspita, M., & Dewi, G. P.
(2024). Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents. Vaccines, 12(8), 938.
https://doi.org/10.3390/vaccines12080938
